Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Peptide Mapping for Biologic Comparability Assessments

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Peptide Mapping for Biologic Comparability Assessments

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in CMC Analytics.

A scientist in a lab coat and gloves loads samples into a ProteinSimple instrument for analysis.

Frequently Asked Questions

When is a formal comparability assessment required for a biologic candidate?

A comparability assessment is triggered by any significant change in the manufacturing process of a biologic or next-generation therapeutic. This includes alterations in scale (e.g., moving from a 50L to a 500L bioreactor), changes to the manufacturing site, modifications to raw materials, or adjustments to the purification process. Regulatory bodies like the FDA and EMA require robust data demonstrating that these changes have not adversely affected the product’s identity, purity, or potency.

How does peptide mapping de-risk IND submissions for next-generation therapeutics?

Peptide mapping provides high-resolution confirmation of a protein’s primary structure, which is directly related to its function and safety profile. For an Investigational New Drug (IND) submission, this analysis serves as a definitive identity test and establishes a baseline for all future manufacturing batches. By confirming the amino acid sequence and identifying post-translational modifications, it minimizes the risk of regulatory delays associated with product characterization and comparability questions.

What is the difference between peptide mapping for monoclonal antibodies versus AAV capsids?

While the core mass spectrometry technique is similar, the application differs based on complexity. For monoclonal antibodies, the focus is on confirming the sequence of heavy and light chains and characterizing glycosylation patterns. For Adeno-Associated Virus (AAV) capsids, the analysis is more complex, involving the characterization of three distinct viral proteins (VP1, VP2, VP3) and their stoichiometric ratios, which directly influence vector infectivity and stability.

A researcher in a lab coat and blue gloves gently holds three white lab mice, symbolizing animal models in scientific research.

Executive Summary

Peptide mapping using mass spectrometry is a required analytical method for establishing the identity and structural integrity of protein-based therapeutics. It is a regulatory expectation for demonstrating comparability after any manufacturing process change. This analysis provides definitive confirmation of the primary amino acid sequence and identifies post-translational modifications (PTMs), directly supporting chemistry, manufacturing, and controls (CMC) packages for IND and BLA submissions. Franklin Biolabs utilizes advanced LC-MS/MS platforms to provide the resolution needed to support product development for complex biologics and next-generation therapeutics.

Establishing Comparability with High-Resolution Analytics

Demonstrating comparability between manufacturing batches of a biologic is a primary regulatory requirement. When a process is scaled, transferred to a new facility, or otherwise modified, sponsors must prove that the product remains structurally and functionally equivalent. Peptide mapping provides the definitive data for this demonstration.

The analysis involves enzymatic digestion of the protein into smaller peptides, which are then separated and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This process generates a detailed fingerprint of the protein, allowing for:

  • Confirmation of 100% sequence coverage for the intended amino acid sequence.

  • Identification and localization of post-translational modifications like oxidation, deamidation, and glycosylation.

  • Detection of sequence variants or impurities that could impact efficacy or immunogenicity.

A digital rendering of a DNA double helix on a dark blue background with floating particles.

The Clinical Impact of Minor Structural Variations

Even single amino acid substitutions can have significant biological consequences. Research into immune responses during gene therapy trials has shown that T-cell responses can be directed against polymorphic peptides, potentially reducing transgene expression and impacting outcomes (PMID: 28137880). This finding underscores the need for analytical methods with sufficient resolution to detect minor sequence variants that may arise during production. High-resolution peptide mapping provides the data to ensure such variants are not introduced during manufacturing changes.

The analytical principles applied by our scientific leadership have a proven track record of supporting accelerated 18-24 month IND timelines. This expertise, established by our core team during their work at the University of Pennsylvania, was instrumental in advancing our partners portfolio of systemic intracellular therapeutics. Franklin Biolabs continues this legacy of analytical excellence within our expansive >100,000 sq ft GxP-compliant facilities, which you can explore further here:.

The data generated through these methods are integral to the robust CMC packages required for global regulatory submissions, including harmonized filings under ICH guidelines. This analytical rigor is a core component of the services available through our Vector | CMC | Analytics Services platform.

Comparability Assessment Methodologies

Feature Legacy Methods (e.g., SDS-PAGE, IEF) Advanced LC-MS/MS Peptide Mapping
Resolution Low to Moderate High (Amino Acid Level)
Information Provides bulk property data (size, charge) Confirms primary sequence, PTMs, variants
Sensitivity Limited for detecting minor variants High sensitivity for low-abundance species
Regulatory Acceptance Supportive, but insufficient as standalone Expected standard for identity & comparability
Application Routine QC, initial characterization Definitive characterization, comparability studies

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities